Engineered proteins from transgenic animals

描述(申请人提供)：生物技术行业正在开发的产品中约有25%是抗体，其中许多抗体是针对人类细胞和组织上的表位的。基于蛋白质相互作用的最新进展和转基因技术的最新发展，我们提出了一种生产具有治疗潜力的抗体的新概念。这一概念的实施将避免许多昂贵和耗时的修改，这些修改通常需要在鉴定出潜在的治疗性单抗后进行，以便优化其药理特性并使其适合大规模生产。通过结合来自体外研究的最新数据和对基因组学的初步了解，我们将扩大可获得的表位范围，从而扩大潜在治疗性抗体的范围。 与公共卫生相关：在过去的15年里，已经开发了20多种治疗性抗体来治疗人类疾病，特别是在自身免疫和癌症领域。我们提出了一种新的方法来获得潜在的治疗性抗体，这种抗体将识别从传统来源无法获得的靶点。此外，这项技术将设计出具有更好的药理属性和更好的制造性能的抗体。这项技术将提供一条具有成本效益的途径，以增加治疗人类疾病的候选疗法的范围。

DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies PUBLIC HEALTH RELEVANCE: During the past 15 years, more than 20 therapeutic antibodies have been developed to treat human disease, particularly in the fields of automimmunity and cancer. We have proposed a novel method to obtain potentially therapeutic antibodies that will recognize targets that cannot be obtained from conventional sources. In addition, the technology will engineer antibodies that have improved pharmacological attributes and better manufacturing properties. This technology will provide a cost-effective route to increasing the range of therapeutic candidates for the treatment of human disease.